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INTRODUCTION
INTRODUCTION
HIV – AIDS  has been the recent infectious disease of great interest, due 
to its extreme immunosuppressive effect  in humans. Of late many studies have 
been  conducted  on  HIV   and  its  manifestations  of  various  organ  system 
disorders.  The  most  dreaded  complications  of  HIV infection  are  due  to  the 
opportunistic infections following severe  immunosuppression, rather than the 
virus  itself,  such  as  pneumocystis  carinii  pneumonia,  tuberculous  and 
cryptococcal meningitis.
Gastro  intestinal  infections  are  also  increased  in  patients  with  HIV. 
Various organisms not usually found in immunocompetent persons colonise the 
GIT in HIV patients,  such as  CMV, Isospora,  Cryptospora,  Herpes etc.  But 
H.pylori has been shown to take a different scenario in HIV infected patients in 
many studies. While H.pylori  has been found to be the most common organism 
in  peptic  ulcer  disease  and  even  in  non  ulcer  dyspepsia  in  the  general 
population, its incidence in HIV positive patients in some studies has been low. 
Hypochlorhydria has been postulated to be one of the causes for this decreased 
incidence.  But still there are some studies that have shown no difference from 
the general population. Such studies in Indian population are also very few.
Many methods of diagnosis are available both non invasive and invasive 
to detect  H.pylori  infection,  such as serological  methods,  stool  antigen tests, 
rapid urease tests and biopsy based tests. Among these the ultra rapid urease 
tests  gives  the  immediate  diagnosis  and  is  relatively  cheaper  and  easier  to 
perform.  Establishing  the  extent  of  prevalence  of  H.pylori  infection  in  HIV 
positive patients is important, due to the complications  associated with chronic 
H.pylori  infection  such  as  adenocarcinoma  of  stomach,  gastric  lymphomas, 
peptic ulcer associated complications such as perforation and bleeding.
REVIEW OF LITERATURE
DISCOVERERS  OF  HIV  :  ROBERT  GALLO  –  FRANCOISE  BARRE 
SINOUSSI & LUC MONTAGNIER
REVIEW OF LITERATURE
HIV
The origin of AIDS and HIV has puzzled scientists ever since the illness 
first  came  to  light  in  the  early  1980s.  The  first  recognised  cases  of  AIDS 
occurred  in  the  USA in  the  early  1980s.  During  that  period,  a   number  of 
homosexual  men in New York and California suddenly began to develop rare 
opportunistic infections, such as pneumocystis carinii pneumonia, and cancers, 
such  as  kaposi’s  sarcoma  that  seemed  stubbornly  resistant  to,  any  form of 
treatment.[1] Luc  Montagnier from Pasteur  Institute,  France,  discovered  the 
causative agent in 1983,and labelled it as LAV -2 lymphadenopathy associated 
virus.[2]. Robert Gallo from USA  also isolated the virus in 1984, and named it 
HTLV- ш, Human T Lymphotropic Virus – ш. The International committee on 
Taxonomy of Viruses redesignated both the viruses and named it  as Human 
Immunodeficiency Virus[3][4].
HIV infection in humans is considered pandemic by WHO. From 1981 to 
2006, AIDS killed more than 2.1million people, including 3,30,000 children. [5]. 
HIV infects about 0.6% of the world's population[6]. A third of these deaths are 
occurring  in  sub-Saharan Africa,  retarding  economic  growth and  increasing 
poverty.[6]. According to current estimates, HIV is set to infect 90 million people 
in Africa, resulting in a minimum estimate of 18 million orphans.[7]
HIV is a member of the genus Lenti virus,[8] part of the family of Retroviridae.[9] 
Lentiviruses are transmitted as single-stranded, positive-sense, enveloped RNA 
viruses. 
TYPES OF VIRUS:
There are two strains of HIV known to exist: HIV-1 and HIV-2.
 HIV-1 is  the  virus  that  was  initially  discovered  and  termed  LAV 
(LYMPHADENOPATHY ASSOCIATED VIRUS)  by Luc Montagnier.  It  is 
more virulent, relatively easily transmitted, and is the cause of the majority of 
HIV infections globally. HIV – 1 has three groups. Major group (M), outlier 
group (O), and new group (N). Major group M is further classified into subtypes 
designated A through H, J, and K. Subtype C has been reported in India.
HIV-2 is less transmittable, less virulent, with long asymptomatic phase 
and is  largely confined to  West  Africa.  It  is  closely related to SIV (Simian 
immunodeficiency virus), causing AIDS like illness in monkeys.
STRUCTURE AND GENOME OF HIV:
It  is  a  spherical  enveloped  virus  of  90  –  120  µm size  with  an  outer 
icosahedral shell and an inner cone shaped core enclosing the RNA proteins – 
as 2 single stranded positive sense RNA copies. The genome of HIV includes 3 
structural genes- gag, pol and env.
STRUCTURE OF HIV
The gag gene codes of core and shell . it produces the proteins p15, p18, 
and p24 – major antigen detected in early stages.
The  env gene  encodes  for  envelope  glycoproteins  gp  160,  which  is 
cleaved into gp 120 and gp 41.
The  pol gene  encodes   for  PRT polymerase  reverse  transcriptase  and 
other viral enzymes.
Apart from these, HIV has 6 regulatory genes.
Tat – transactivating gene – expression of viral genes
Nef – negative factor gene – down regulates viral replication 
Rev – regulator of virus gene – enhances expression of structural proteins
Vif – viral infectivity factor gene – influences infectivity of viral particles
Vpu – only in HIV 1 –  vpx in HIV 2 -  enhances maturation and release of 
progeny from cells.
Vpr – stimulates promoter region of the virus
LTR – long terminal repeat sequences.
TRANSMISSION OF HIV:
The main modes of transmission of HIV includes:
 Sexual – hetero and homosexual transmission
 Vertical / transplacental transmission from mother to fetus
 Parenteral transmission through:-
1. Blood and its products transfusion,
2. Organ transplantation
3. Injection drug abuse
 Through contaminated instruments- occupational
THE VIRAL LIFE CYCLE:
Upon entry of the target cell the CD4+ T cells in initial stages, the viral 
RNA genome is  converted  to  double-stranded  DNA by  a  virally  encoded 
reverse transcriptase that is present in the virus particle. This viral DNA is then 
integrated into the cellular DNA by a virally encoded integrase, along with host 
cellular co-factors, so that the genome can be  transcribed. After the virus has 
infected the cell, two pathways are possible: either the virus becomes latent and 
the  infected  cell  continues  to  function,  or  the  virus  becomes  active  and 
replicates, and a large number of virus particles are liberated that can then infect 
other cells. With prolonged infection CD4+ T cell count decreases progressively 
resulting in both qualitative and quantitative defects  in lymphocyte function. 
Other cells infected include B- lymphocytes, and macrophages.
                                
LIFE CYCLE OF HIV
CLINICAL MANIFESTATIONS:
HIV infection has basically four stages: 
 Incubation period
 Acute infection
 Latency stage 
 AIDS. 
The initial incubation period upon infection is asymptomatic and usually 
lasts between three to six weeks. 
The second stage,  Acute HIV Syndrome which lasts for an average of 
one  week  to  three  months,  and  includes  symptoms  such  as  fever, 
lymphadenopathy,  pharyngitis ,  rash,  myalgia,  arthralgia,  malaise,  anorexia, 
vomiting, diarrhea, weight loss, neurologic disorders such as aseptic meningitis, 
encephalitis, peripheral neuropathy, myelopathy, dermatologic features such as 
erythematous maculopapular rashes  and mouth and esophageal ulcers.[10].
The Latency stage, which occurs third, shows few or no symptoms and 
can last anywhere from two weeks to twenty years and beyond. The long term 
non progressors and elite non progressors have little decline in CD4+ T cell 
count and low levels of viremia. The CD4+ T cell decline is 50 cells /µl/yr. 
 AIDS,  the  fourth  and  final  stage  of  HIV  infection  presents  with 
symptoms of various opportunistic infections.
The current CDC classification system for HIV infected adolescents and 
adults categorizes persons on the basis of clinical conditions associated with 
HIV infection and CD4+ T cell counts.
CLINICAL CATEGORIES OF HIV INFECTION:
CATEGORY A:
Consists of one or more of the conditions listed below in an adolescent or 
adult  [>13  years]  with  documented  HIV  infection.  Conditions  listed  in 
categories B and C must not have occurred.
 Asymptomatic HIV infection
 Persistent generalised lymphadenopathy
 Acute [primary] HIV infection with accompanying illness or history of 
acute HIV infection.
CATEGORY B:
Consists  of  symptomatic  conditions  in  an  HIV infected  adolescent  or 
adult that are not included among conditions listed in clinical category C and 
that meet atleast one of the following criteria:
1. The conditions are attributed to HIV infection or are indicative of a defect 
in cell mediated immunity: or
2. The conditions are considered by physicians to have a clinical course or 
to require management that is complicated by HIV infection. Examples 
include, but are not limited to, the following
 Bacillary angiomatosis
 Candidiasis, oropharyngeal (thrush)
 Candidiasis, vulvovaginal; persistent, frequent, or poorly responsive to 
therapy.
 Cervical dysplasia (moderate or severe)/cervical carcinoma in situ
 Constituitional symptoms, such as fever (38.5°C) or diarrhea lasting 
>1 month.
 Hairy leukoplakia, oral
 Herpes zoster   (shingles),  involving atleast two distinct  episodes or 
more than one dermatome
 Idiopathic thrombocytopenic purpura
 Listeriosis
 Pelvic  inflammatory  disease,  particularly  if  complicated  by 
tuboovarian abscess
 Peripheral neuropathy
CATEGORY C:
Conditions listed in the AIDS surveillance case definition.
 Candidiasis of bronchi, trachea, or lungs
 Candidiasis, esophageal
 Cervical cancer, invasive
 Coccidiomycosis, disseminated or extrapulmonary
 Cryptococcosis, extrapulmonary
 Cryptosporidiosis, chronic intestinal (>1 month’s duration)
 Cytomegalovirus disease (other than liver, spleen, or nodes)
 Cytomegalovirus retinitis (with loss of vision)
 Encephalopathy, HIV related
 Herpes  simplex,  chronic  ulcer(s)  (>1month’s  duration);  or  bronchitis, 
pneumonia or esophagitis
 Histoplasmosis, disseminated or extrapulmonary
 Isosporiasis, chronic intestinal (>1 month’s duration)
 Kaposi’s sarcoma
 Burkitt’s lymphoma or equivalent term
 Lymphoma, primary, or brain
 Mycobacterium  avium  complex  or  M.Kansasii,  or  disseminated  or 
extrapulmonary
 Mycobacterium tuberculosis, any site (pulmonary or extraplmonary)
 Mycobacterium,  other  species  or  unidentified  species,  disseminated  or 
extrapulmonary
 Pneumocystis jiroveci pneumonia
 Pneumonia, recurrent 
 Progressive multifocal leukoencephalopathy
 Salmonella septicaemia, recurrent
 Toxoplasmosis of brain
 Wasting syndrome due to HIV
1993 REVISED CLASSIFICATION SYSTEM FOR HIV 
INFECTION AND EXPANDED AIDS SURVEILLANCE CASE 
DEFINITION FOR ADOLESCENTS AND ADULTS:
Clinical categories
CD4+Tcell 
categories
A  Aymptomatic, 
Acute  (primary) 
HIV or PGL
B  Symptomatic, 
Not  A  or  C 
Conditions
C AIDS- Indicator 
Conditions
>500/µl A1 B1 C1
200-499/µl A2 B2 C2
<200/µl A3 B3 C3
LAB DIAGNOSTIC METHODS FOR HIV:
Includes tests for immunodeficiency and specific tests for HIV.
TESTS FOR IMMUNODEFICIENCY:
CD4+ T CELL COUNT:-
Best indicator for immunological status of the patient. CD4+ T cell count 
is  estimated  by flow cytometry.   Either  absolute  CD4+ T cell  count  or  the 
percentage of CD4+ T cell count especially in spleenectomised individuals can 
be taken.  A CD4+ T cell  count of 200/µl would be approximately 15%.  A 
CD4+ T cell count less than 350/µl is an indication for ART.
TOTAL LEUCOCYTE COUNT:-
Leucocytopenia and lymphocytopenia.
RAISED Ig G AND Ig A LEVELS.
DIMINISHED CELL MEDIATED IMMUNITY:
Suppressed  T cell mediated, delayed hypersensitivity reactions  as shown 
by skin tests.
SPECIFIC TESTS FOR HIV:
ANTIBODY DETECTION:-
ELISA/EIA:-
This is the most widely used screening method. It has a sensitivity of > 
99.5 %.  Hence the false  positivity  is  also present   with conditions such as 
influenza  vaccination,  hepatic  disease  an  auto antibodies.  Direct  solid  phase 
antiglobulin ELISA is the most commonly used method. Antigen obtained from 
cell cultures and recombinant techniques represents all subtypes of both  HIV 1 
AND HIV 2. The antigen is coated on microtitre wells and test serum is added 
to it. If antibody to HIV is present in the serum it binds to the antigen. After 
washing away the  unbound serum anti  human immunoglobulin  bound to  an 
enzyme is  added,  followed by a  colour  forming  substrate.  If  the  test  serum 
contains anti HIV antibody then a photometrically detectable colour is formed 
and can be read by a special ELISA reader.
The first generation ELISA tests detect the anti HIV- 1 antibodies of Ig 
G type using  antigens derived from  virus grown in cell cultures.
The  second generation ELISA tests detect the anti HIV  -  1 and anti 
HIV – 2 antibodies using recombinant antigens.
Third generation ELISA tests detect  Ig M antibodies using synthetic 
oligopeptides.
The  fourth generation ELISA tests combine detection of antibodies to 
HIV  with  detection  of  the  p24  antigen  of  HIV.  Hence  more  helpful  in 
identifying individuals with infection during the window period.
THE P24 ANTIGEN CAPTURE ASSAY:-
This ELISA test uses the anti p24 antibody to detect p24 antigenemia in 
serum.  It  can  detect  upto  50%  positivity  in  pts  with  conventional  ELISA 
negativity, hence is most useful in detecting persons recently exposed and in the 
window period.
The  other  screening  methods  include   Indirect  Immunoflourescence 
Assay and Radio Immuno Precipitation Assay.
CONFIRMATORY TEST:
WESTERN BLOT TEST:-
In  this  test,  HIV proteins  separated  according  to  their  electrophoretic 
mobility   by  polyacrylamide  gel  electrophoresis  are  blotted  onto  strips  of 
nitrocellulose paper. The strips are reacted with test sera and then with enzyme 
conjugated  antihuman  globulin.  A  suitable  substrate  is  then  added  which 
produces a prominent colour band where the specific antibody has reacted with 
the viral proteins. The test is considered positive if it shows bands against at 
least two of the following gene products: p24, gp 41, gp120/160.
DIRECT VIRAL DETECTION:
HIV culture from plasma or cells .  Direct detection of viral nucleic acids 
such as  DNA, the reverse  transcriptase PCR for   viral RNA,  and branched 
chain DNA – b DNA assay.
UPPER GASTROINTESTINAL MANIFESTATIONS IN HIV
ORAL LESIONS:- 
THRUSH / CANDIDIASIS:
Caused   by  candida  albicans  is  seen  as  white  cheesy  exudates  on 
erythematous mucosa in oropharynx.  Generally occurs in HIV pts with CD4 
cell counts less than 300/µl.  The organism can be detected by KOH  staining 
showing  pseudohyphal  elements.  Treatment  includes  clotrimazole  or  oral 
fluconazole  100mg/d  for  14  days.  Itraconazole,  i.v.  Amphotericin  B  or 
caspofungin may also be tried.
ORAL HAIRY LEUKOPLAKIA:
Seen as white, frondlike lesions on the lateral borders of tongue is usually 
associated with Epstein barr virus infection, but is not a premalignant condition. 
HPE  shows  hyperparakeratosis,  acanthosis  and  vacuolations  in  prickle  cell 
layer. Patients with severe infection can be treated with podophyllin.
                                         ESOPHAGEAL CANDIDIASIS
                                     CYTOMEGALOVIRUS ULCER 
APTHOUS ULCERS:
These are painful pin point ulcers commonly involving the oropharynx. 
Thalidomide is the drug of choice.
Other organisms causing oral infection in HIV patients are cryptococci 
and histoplasma.
ESOPHAGEAL DISEASES:- 
ESOPHAGEAL MONILIASIS:-
The commonest cause of odynophagia in HIV Individuals is esophageal 
moniliasis.  It  is  considered  as  an  AIDS  defining  illness.  Dysphagia  can 
sometimes  occur  rarely  due  to  moniliasis.  The  endoscopic  appearance  of 
Candida esophagitis is well recognized. Kodsi et al [11].  reported the endoscopic 
findings in 27 immunosuppressed with Candida esophagitis. The diagnosis was 
established  primarily  by  brush  cytology,  with  very  few  patients  undergoing 
endoscopic mucosal  biopsy for histopathologic assessment.  This study forms 
the basis  for  most  of  the grading scales  currently used to assess  severity  of 
Candida esophagitis. More recently, a grading scale has been proposed based 
on the severity of plaque formation.[11]. Grade I was said to be present when rare 
plaques were seen throughout the esophagus, to Grade IV, which was said to be 
present with severe plaque formation resulting in luminal narrowing. 
HSV ULCERS IN ESOPHAGUS
HPE OF CMV ESOPHAGITIS
Treatment involves fluconazole 200mg/d  or itraconazole 200mg/d oral or 
i.v. for 14 – 21 days. Other drugs include i.v. amphotericin B, caspofungin and 
voriconazole. HAART is the effective treatment for recurrent esophagitis. The 
incidence  of  esophageal  infections  in  patients  with   AIDS  has  fallen 
dramatically,[12] and the prognosis of these patients has improved[13] due to the 
widespread use of highly active antiretroviral therapy (HAART).
 VIRAL ESOPHAGITIS  is  an  important  cause  of  morbidity  in  HIV 
disease. In these patients, both  HSV and  CMV  disease typically occur in the 
latter stages of immunodeficiency (absolute CD4 lymphocyte count <100/µL), 
[2][14].  Although some studies  of  symptomatic  patients  undergoing endoscopy 
prior to any therapy have documented an equivalent prevalence of CMV and 
HSV esophagitis,[15[16] a  prospective study of  100 HIV-infected patients  with 
well-defined  esophageal  ulcer  showed  CMV  esophagitis  alone  to  be 
significantly more common than HSV esophagitis alone, occurring in 45% and 
5% of patients, respectively.[17]. This low prevalence of HSV esophagitis was 
not related to the use of acyclovir therapy. This study also demonstrated HSV 
and  CMV  co-infection  in  four  patients.  Other  reported  viral  causes  of 
esophageal disease in patients with AIDS include Epstein-Barr virus and human 
papilloma virus. HIV has also been proposed as a cause of esophageal disease. 
CMV infection commonly causes single large ulcer whereas HSV infection is 
associated with well  circumscribed  multiple  superficial   small  ulcers.  CMV 
also  causes,  gastritis,  gastric  and  duodenal  ulcers,  enteritis  and  mesenteric 
vasculitis.  Diagnosis  is  by  endoscopic  biopsy  ,  PCR and CMV antigenemia 
PP65. Treatment is with i.v. gancyclovir or valgancyclovir and HAART.
NON INFECTIOUS ESOPHAGEAL DISORDERS IN HIV:-
OROPHARYNGEAL  AND ESOPHAGEAL  ULCERATION  has  been 
observed  during  the  seroconversion  illness.  These  esophageal  ulcerations 
appeared  endoscopically  as  multiple,  small,  and  shallow  ulcers.[18].Mucosal 
biopsy demonstrated ulcer tissue without any etiologic agent .
IDIOPATHIC ESOPHAGEAL ULCER:-  
IEU  is  seen  in  the  later  stages  of  immunodeficiency  when  the  CD4 
lymphocyte count is less than 100/µL.[18]. These ulcers are variable in size and 
appearance. IEU is a diagnosis of exclusion. 
NEOPLASMS:-
Involvement  of  the  esophagus  with  hodgkins  and  non  hodgkins 
lymphoma remains uncommon, though it is commonly seen in AIDS patients. 
Adenocarcinoma of the esophagus associated with Barrett's epithelium has been 
reported  in  HIV-infected  patients  where  the  tumor  appeared  as  a  fleshy 
ulcerated  mass  lesion  at  the  gastroesophageal  junction.[19]. Typical  Barrett's 
epithelium was identified and confirmed at the time of resection. 
KAPOSI'S SARCOMA:-
Kaposi's  sarcoma  is  common  in  those  with  cutaneous  disease,  and 
esophageal lesions are generally an incidental finding at the time of endoscopy 
performed for other reasons. However, isolated gastrointestinal disease without 
cutaneous disease has been noted. Gastric or duodenal involvement appears to 
be more common than esophageal diseases. These tumors typically involve the 
submucosa therefore biopsy should be taken from deeper tissues. HPE  of the 
tumor shows multiple vascular channels .
GERD IN HIV PATIENTS:
Hypochlorhydria has been variably observed in patients with AIDS[20][21] 
and was speculated to be one reason for the relatively low prevalence of GERD. 
In a series of 100 HIV infected patients with esophageal ulcer, reflux disease 
was the etiology in four.[19].  More recently, however, with the use of HAART, 
GERD is becoming more common.[18].
Anti retroviral drugs such as zidovudine and zalcitabine can also cause 
esophagitis.
Among the conditions involving the stomach are Kaposi’s sarcoma and 
lymphoma.  Infections  involving  stomach  are  uncommon.  Interestingly 
incidence of H.pylori has been found to be less in HIV patients. [28-32].
HELICOBACTER PYLORI
Originally  named  Campylobacter  pylori,   Helicobacter  pylori  was 
discovered by  WARREN and MARSHALL in Australia in 1983. H. Pylori 
now is known to have caused human infection since ancient times as H.pylori 
antigens  were  detected  in  mummies  of  pre-columbian  era  in  USA.  H.pylori 
infects 60% of humans worldwide. Apart from humans the only other animal it 
infects is monkeys.
The transmission of  H.pylori, though not exactly known may be oro-oral, 
feco-oral or gastro-oral and is facilitated by overcrowding and poor hygiene and 
hence the infection is more prevalent in developing countries like India, more so 
among the low socioeconomic status people.
H.pylori  is  a  gram  negative  spiral  microaerophillic  bacteria  with  a 
unipolar tuft of flagella which colonises the human gastric mucus , but does not 
invade the mucosa.  It produces oxidase,  catalase,  phosphatase,  and hydrogen 
sulphide. But its unique feature is the production of urease and this is the basis 
of  diagnostic  tests  in  Rapid  Urease,  Urea  breath  tests.  Its  virulence  factors 
includes  the  unipolar  flagella  that  facilitate  rapid  movement  into  the  mucus 
layer. Urease changes the acidic pH  to alkaline which facilitates the survival of 
the  organism  in  the  gastric  mucosa.  Production  of  adhesins  which  help  in 
binding to gastric mucosa like N-acetyl neuraminyl lactose binding fibrillar 
HELICOBACTER PYLORI STRUCTURE AND VIRULENCE FACTORS:
haemagglutinin  which bind to carbohydrate receptors on mucosal cells. 
These may have a role in genetic susceptibility to H. Pylori infections.
Production  of  inflammatory  mediators  such  as  lipopolysachharides, 
leukocyte  recruitment  and  activating  factors,  vacuolating  toxins(vac  A)  , 
cytotoxin  associated  antigen  (cag  A),  outer  membrane  inflammatory  protein 
(oip),   heat  shock  proteins  play  an  important  role  in  causing  gastric 
inflammation.
Cag A , an antigenic protein, encoded by cag A gene in cag pathogenecity 
island  is  associated  with  severe  inflammatory  response.  Cag  A  undergoes 
phosphorylation  ,  causes  actin  polymerisation  in  infected  cells,  enhances 
inflammatory response. It is more often found in patients with peptic ulcers and 
gastric adenocarcinoma.
Acute  infection  with  H.pylori  results  in  neutrophillic  infiltrate  and 
hypochlorhydria  in  initial  stages  and  when  the  infection  subsides,  the 
inflammation decreases, the baseline pH returns to normal. H. pylori colonizes 
gastric  mucosal  (epithelial)  cells  in  the  stomach,  and  metaplastic  gastric 
epithelium in the duodenum or esophagus, but does not colonize the rest of the 
intestinal epithelium. The organism survives in the mucous layer that coats the 
epithelium,  and  causes  chronic  inflammation  of  the  mucosa  .  In  chronic 
inflammation the lymphocytic infiltrates are seen at the junction of muscularis 
mucosa and lamina propria. Lymphoid follicles are seen more at antrum. 
PATHOGENESIS OF H.PYLORI INDUCED ULCER:
Inflammatory  mediators  released  by  H.pylori  downregulate  somatostatin 
production and increase  gastrin  production.  Hypergastrinemia  results  in  acid 
secretion and gastric mucosal injury and peptic ulcer disease.
Types of chronic gastritis caused by H.pylori:
1. Chronic superficial gastritis
2. Atrophic gastritis :– 
a. Diffuse corporal atrophic gastritis – 31%
b. Antral predominant atrophic gastritis
c. Multifocal atrophic gastritis – 24%
It has been classified as 
1) type A with parietal cell antibodies, 
2) type B without parietal cell antibodies and 
3) type C with patchy atrophy. 
 Atrophic gastritis[23]   predominant in body of stomach is associated with 
pernicious  anaemia.  Also  iron  deficiency  anaemia  is  noted  in  patients  with 
H.pylori infection. Apart from the complications usually associated with peptic 
ulcer disease,  chronic gastritis with H.pylori is associated with an increased risk 
to intestinal metaplasia and gastric adenocarcinoma and gastric maltoma.[24].
THE ULTRA RAPID UREASE TEST
DIAGNOSTIC TESTS:
INVASIVE TESTS:
1. Mucosal biopsies and staining:  Haematoxylin and eosin
                                                    Warthin starry silver stain
                                                    Genta and El-Zimaity triple stains
2. Rapid urease tests of biopsy
Rapid urease test:  mucosal specimen is placed in an urea rich medium 
(2-10%). If H.pylori is present, the urease produced by it converts  urea 
into ammonia and carbondioxide. The increase in pH changes the color of 
the solution when an indicator phenol red is added to it.
3. Culture:
The organism can be cultured in media containing chocolate agar and in 
campylobacter media with 5-20% CO2.
NON INVASIVE TESTS:
1) SEROLOGY:
Among the serologic methods available, ELISA is the most  frequently 
employed because of its speed, simplicity and reproducibility. The sensitivity 
and specificity of the ELISA depend on the antigen preparation employed. The 
first generation ELISA detects the Ig G Antibodies. Second generation EIA that 
employs  a  well-characterized  and  highly  immunogenic  purified  H.  pylori-
specific  multi-component  antigen  preparation  containing  urease  and  free  of 
cross-reacting   flagellar  proteins.  Serologic  tests  are  useful  for  the  initial 
diagnosis  of  H.  pylori infection  but  are  less  useful  to  confirm  cure  after 
antimicrobial therapy. [25]
2) UREA BREATH TESTS:
Urea breath tests use urea labeled with either 13C or 14C that is ingested. If 
urease is present in the stomach as a consequence ofH. pylori infection, labeled 
carbon dioxide  will  be  split  off  and absorbed  into  the  circulation  where  its 
presence can be determined by analysis of expired breath. 13C-labeled urea has 
the advantage of  not  being radioactive but  requires  a  mass  spectrometer  for 
analysis.[26].  14C-labeled urea can be measured with a scintillation counter but 
does expose the individual to a small, long-lasting dose of radioactivity
3) STOOL ANTIGEN TEST:-
This is an enzyme immunoassay method for the detection of Helicobacter 
pylori  antigens in human stool. This  test  is  susceptible  to inaccuracy during 
concomitant administration of PPIs.[27]
4) PCR METHODS:-
Stool PCR method can be used to detect  H. pylori, virulence genes, and 
in drug resistance studies.
TABLE 1 - COMPARISONS OF VARIOUS METHODS OF DETECTION 
OF H.PYLORI
Features of the tests HPE Culture RUT ELISA UBT SAT PCR
Sensitivity% 90 86 88-92 90-100 95-100 91 93-96
Specificity% 88 100 92 - 100 91-100 95-100 93 100
Invasive + + + — — — —
Expensive + + — — — — +
Results within 24 hrs — — + — + + +
Confirms eradication — — — — + — +
Influence of PPI and 
antibiotics
+ + + — + — —
HPE-histopathology, RUT- rapid urease test, ELISA-enzyme linked 
immunosorbent assay, UBT-urea breath test, SAT-stool antigen test, + yes, — no.
TREATMENT OF H.PYLORI INFECTION:-
Cure  of  H.  pylori infection  is  not  easy  and  requires  combinations  of 
antibiotics often with additional non antibiotic adjunctive agents; single agents 
are ineffective.  Successful cure of infection requires at least two antimicrobial 
agents. The duration of therapy required to yield a high cure rate is unknown. 
Generally, 1 week of therapy is less effective than longer duration.  Compliance 
is important for successful cure of the infection.
H.pylori  eradication is  defined as  negative test  for  H.pylori  atleast  28 
days after therapy. 
FACTORS MODIFYING TREATMENT:
Bismuth  and PPIs   specifically  inhibit  the  bacterial  enzyme urease  so 
enzyme based tests might fail to detect the infection.
H.pylori tends to move to proximal stomach during suppression of acid 
secretion. So biopsy based tests become inaccurate.
C14 and C13 are most accurate because they sample the whole stomach 
and so regarded as gold standard
Serology  is  not  useful  to  detect  eradication  as  it  takes  6  months  for 
antibody titres to fall significantly.
Dual  therapy  with  combination  of  omeprazole  or  ranitidine  bismuth 
citrate and either amoxicillin or clarithromycin for 2 weeks eradicates H.pylori 
in 50-80%. In triple therapy eradication may be 50%. One week, twice daily PPI 
based triple therapy regimen eradicate about 90%. Second line regimen include 
7  days  treatment  with  omeprazole  and  3times  daily  amoxycillin  and 
metronidazole or a PPI based quadruple therapy regimen.
                   TABLE 2:   DUAL REGIMENS WITH AMOXYCILLIN
REGIMEN 1 REGIMEN 2
DRUG Omeprazole Amoxycillin Ranitidine 
Bismuth 
citrate        
Amoxycillin
DOSE (mg) daily 20-40mg 
twice 
750mg thrice 
1gm twice
400-800mg 
twice
500mg four 
times.
DURATION 2 weeks 2 weeks
EFFICACY 52-85% 65%
SIDE EFFECTS diarrhoea
                 
                   TABLE 3:   DUAL REGIMENS WITH CLARITHROMYCIN
REGIMEN 1 REGIMEN 2
DRUG Omeprazole Clarithromycin Ranitidine 
bismuth 
citrate
Clarithromycin 
DOSE(daily) 40mg once 500mg thrice 400mg twice 500mg twice
DURATION 2 weeks 2 weeks
EFFICACY 80% 80%
SIDE 
EFFECTS
Taste disturbances 
diarrhoea
TABLE 4:   TRIPLE REGIMENS WITH AMOXYCILLIN AND 
METRONIDAZOLE
REGIMEN 1 REGIMEN 2 REGIMEN 3
DRUG Omeprazole + 
Amoxicillin +
Ranitidine + 
Amoxicillin + 
Bismuth+tetracycline/
Amoxicillin +
Metronidazole Metronidazole metronidazole
DOSE(daily) 40mg once +
500mg thrice +
400mg thrice
300mg once +
750mg thrice +
500mg thrice
120mg 4 times +
500mg 4 times +
200-400mg 4 times
DURATION 7 days 12 days 2 weeks
EFFICACY 95% 90% 60-90%
SIDE EFFECTS Diarrhoea
TABLE 5:   LOW DOSE TRIPLE THERAPY
REGIMEN 1 REGIMEN 2
DRUGS PPI+Clarithromycin+ 
metronidazole
PPI+  Amoxycillin+ 
clarithromycin
DOSE Once/twice  daily  + 
250mg twice+
400mg twice
Twice +
1gm twice+ 
250-500mg twice
DURATION 7days 7days
EFFICACY 90% 90%
SIDE EFFECTS Uncommon : diarrhoea, nausea with metronidazole
QUADRUPLE THERAPY
PPI (once/twice daily), colloid bismuth sub citrate (120 mg four times 
daily), tetracycline (500 mg four times daily), metronidazole (400-500mg 3 or 4 
times daily)
Duration of therapy – seven days
Efficacy :– 85 – 95%
Side effects – diarrhoea, nausea
SEQUENTIAL THERAPY
DAY 1 – 5
Proton pump inhibitors(PPI) twice a day
Amoxicillin 1 gm twice a day
DAY 6-10 
Proton pump inhibitors(PPI) twice a day
Clarithromycin 500 mg twice a day
Tinidazole 500 mg twice a day.
UPPER GASTRO INTESTINAL ENDOSCOPY
EVOLUTION:
The  first  practical  rigid  upper  gastrointestinal  endoscope  was 
demonstrated by kussmaul  in 1868 when he performed gastroscopy with the 
help  of  a  cooperative  sword  swallower.  Later  on  many  workers  made 
modifications  and improvement  in  the endoscope.  Hirschowits  et  al  in 1957 
constructed  flexible  fibreoptic  gastroscope.  The  invention  of  charged couple 
device in 1969 made a revolution in endoscopic imaging by allowing the image 
to be modified into digital  signal  and can be visualised through a television 
screen.
INDICATIONS:
1. It can be used as a diagnostic procedure in evaluating all of the upper 
gastrointestinal problems. 
2. Besides direct visualisation it allows tissue sampling.
3. Diagnostic  procedures  such  as  endoscopic  retrograde  cholecysto-
pancreatography can be done.
4. Therapeutic  applications  like  stricture  dilatation,  sclerotherapy,  foreign 
body removal, polypectomy etc.
CONTRAINDICATIONS:
For the patients who can give informed consent and is able to cooperate 
when appropriately sedated, there is virtually no contraindication in performing 
endoscopic procedure. However, the risks are increased by 1.Gastrointestinal 
abnormalties,
2. Serious systemic disease, 
3. Recent myocardial infarction, 
4. Post operative states, 
5. Aneurysm of aorta, 
6. GI perforation.
PREPARATION OF THE PATIENT:
A well informed consent explaining the procedure and instructions to the 
patient  is  a  mandatory one.  Elective endoscopy should be done only after  a 
period of absolute fasting for at least 6 hrs prior to the procedure. For  practical 
purposes it is done after 8 hrs of fasting.
The  dentures  and  eye  glasses  should  be  removed.  The  pharynx  is 
anaesthetised by a topical agent such as xylocaine 4% viscous. Some authors 
suggest i.v medications such as 20 to 125 mg of meperidine or 5 to 15 mg of 
midazolam for a better relaxation. General anaesthesia is rarely required. The 
patient is put in the left lateral position and the whole upper GI tract upto the 2nd 
part of duodenum is systematically examined.
COMPLICATIONS:
The overall occurrence rate of complications from this procedure is less 
than 0.1% and the mortality rate is now less than 0.08%.
Possible misadventures include:
1) Perforation
2) Bleeding cardiopulmonary arrest
3) Reactions to medications
4) Infection
AIMS AND OBJECTIVES
AIM & OBJECTIVES OF THE STUDY
1. To evaluate the findings of upper gastrointestinal tract in HIV positive 
patients.
2. To study the prevalence of  Helicobacter pylori  in HIV positive patients.
3. To compare the prevalence of Helicobacter pylori among HIV positive 
patients according to their immunity status assessed by CD4 count.
MATERIALS AND METHODS
MATERIALS AND METHODS
PLACE OF STUDY:                                       Department of medicine
                                                                         Madurai medical college
TYPE OF STUDY:                                         Cross sectional study
ETHICAL COMMITTEE APPROVAL:       The present project was 
                                                                      approved by ethical  committee
Govt. Rajaji Hospital, Madurai
COLLABORATING DEPARTMENT:          Department of Medical      
                                                                         Gastroenterology
                                                                         Department of S.T.D.
CONSENT:                                                      Informed consent was obtained
                                                                         from the participants
CASE SELECTION:
The inclusion criteria were:
1) Patients aged 18 yrs and above
2) Patients with complaints of dyspeptic symptoms
3) Patients confirmed HIV positive.
4) HIV negative patients for controls.
Criteria for exclusion were:
1) Intake of antibiotics metronidazole  or PPI within a period of 2 weeks
2) Patients on NSAIDS.
3) Patients with severe systemic illness.
4) Acute GI bleed.
5) Pregnancy 
The patients were divided into two groups , the study cases included the 
HIV positive patients (101) and the controls included the HIV negative patients 
(106). The HIV positive  patients were again divided into four groups based on 
their CD4 + T Cell counts, as group CD1, including patients with CD4 counts 
less than 100 cells /µl, group CD2 with counts 100-200 cells /µl, group CD3 
with counts 200-500 cells /µl and group CD4 with CD4 counts >500 cells /µl.
METHODS:
A detailed history and clinical examination  was taken for every patient. 
Baseline investigations were done to rule out major systemic illness. HIV status 
was confirmed with ELISA  and CD4 estimation was done with flow cytometry. 
Endoscopy was done in patients after obtaining informed consent and an over 
night fast. OGD was done using flexible fibreoptic endoscope. Three mucosal 
samples were obtained from stomach. Two from antrum and one from body of 
stomach. One of the samples from antrum was used for RUT test. The other two 
samples were sent for HPE, using haematoxylin  and eosin stains.
Separate biopsy forceps were used in HIV patients. The scope and biopsy 
forceps were sterilised with gluteraldehyde and washed with distilled water after 
every procedure. 
THE ULTRA RAPID UREASE TEST:
The RUT was done with freshly prepared 2% urease solution in sterile 
distilled  water.  1  ml  of  urease  solution  is  taken.  After  placing  the  gastric 
mucosal sample, 1 ml of Phenol red indicator  is added to test the presence of 
alkaline ph. The purpose of this test is to identify the presence of urease enzyme 
produced by H.pylori which hydrolyses urea in the solution to ammonia. This 
creates an alkaline solution which is identified the phenol red indicator which 
changes from yellow to pink in alkaline medium. One antral sample is placed in 
the urease solution and observed for colour change over a period of 12 hrs. If no 
colour change is seen till 12 hrs, then the test is supposed to be negative.
Advantages of RUT test:
1. The test is 90% sensitive and 100% specific for H.pylori.
2. The test is inexpensive and easily available and easily done.
3. The results are also obtained soon.
Disadvantages 
1. It requires an invasive procedure of endoscopyand hence cannot be used 
as a community screening test.
2. And, when the distribution of H.pylori is patchy in gastric mucosa , the 
test may come false negative, depending on the site of biopsy.
HPE of biopsy sample:
The two samples one from antrum and one from the body of stomach 
were  sent  for  histopathological  examination  with  haematoxylin  and  eosin 
staining, for the presence of any lymphocytic cell infiltrates. 
Statistical Tools 
The information collected regarding all the selected cases were recorded 
in a Master  Chart.  Data analysis was done with the help of  computer  using 
Epidemiological Information Package (EPI 2008).
        Using this software range,  frequencies,  percentages,  means,  standard 
deviations, chi square and  'p'  values were calculated. Kruskul Wallis chi-square 
test  was  used  to  test  the  significance  of  difference  between  quantitative 
variables and Yate’s test for qualitative variables. A 'p' value less than 0.05 is 
taken to denote significant relationship.
RESULTS AND 
OBSERVATIONS
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TABLE 1:- AGE DISTRIBUTION
Age group Study cases Controls
No. % No. %
Upto  30 years 23 22.8 19 17.9
30 to 39 years 48 47.5 30 28.3
40 to 49 years 16 15.8 22 20.8
50 to 59 years 12 11.9 15 14.2
60  and above 2 2.0 20 18.9
Total 101 100 106 100
Range
Mean 
S.D
19-65 yrs
36.6 yrs
10.0 
18-75 yrs
43.2 yrs
14.2
p  0.0006   significant
Total no. of HIV patients – 101
Total no. of HIV negative controls – 106
Most of the patients included were younger individuals in their thirties in 
both study cases and controls
                                               
                         
FIGURE 2 – SEX DISTRIBUTION:
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TABLE NO.2 -  SEX DISTRIBUTION:-
Sex Study cases Controls
No. % No. %
Male 68 67.3 64 60.4
Female 33 32.7 42 39.9
p 0.3707  Not significant
                 
There were around 60% of males and 40% females in each group.
TABLE – 3:- DRUG PROFILE AMONG HIV PATIENTS
RUT Study cases
No. %
ART 46 45.5
Ranitidine 5 5.0
Cotrimoxazol
e
29 28.7
Fluconazole 27 26.7
Anti TB drugs 12 11.9
Total 101 100
ART not given 55 54.5
Total 101 100
Patients who were on PPI were excluded from the study. 
45 HIV patients were on ART and 55 patients were not on ART. 
27 patients were on fluconazole who had CD4 counts usually less than 
200.
FIGURE 3 – CD4 COUNT STATUS AMONG HIV PATIENTS:-
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               TABLE NO. 4 – CD4 COUNT STATUS AMONG HIV 
PATIENTS:-
CD4 + T Cell 
Counts in 
Cells / µl
Study 
cases
No. %
CD-1    < 100 16 15.8
CD-2    100 – 
200
22 21.8
CD-3    200 – 
500
41 40.6
CD-4      > 500 22 21.8
Total 101 100
Range
Mean
S.D
14 – 1197
347
282
Patients were grouped into four categories based on CD4 count. 
Patients with counts less than 100 cells /µl were grouped in CD 1, 100 – 
200 cells /µl in CD2, 200 – 500 cells /µl in CD3, and > 500 cells /µl in 
CD4.
FIGURE 4 -  RUT IN HIV CASES AND CONTROLS:
               
TABLE NO 5 - RUT POSITIVITY AMONG HIV PATIENTS AND 
CONTROL CASES
RUT Study cases Controls
No. % No. %
Positive 39 38.6 78 73.6
Negative 62 61.4 28 26.4
p 0.0001  Significant
The no of RUT positive patients among HIV patients is 39 and in 
controls is 78. This shows a significant lower incidence of H.pylori 
positivity (38%) among HIV patients when compared to control 
cases(73%)with a significant p value 0.0001
               
                    
FIGURE 5- H.PYLORI POSITIVITY IN RELATION TO CD 4 COUNT.
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Table 6 – RUT AND CD4 COUNT STATUS IN HIV PATIENTS:
CD4 + T Cell 
count / µl
            RUT 
positive
RUT 
negative
No. % No. %
CD-1    < 100 3 18.8 13 81.3
CD-2    100 – 200 6 27.3 16 72.7
CD-3    200 – 500 16 39 25 61
CD-4      > 500 14 63.6 8 36.4
Range
Mean
S.D
61-1080
446.5
297.6
14 – 1199
284.4
254.2
P 0.003   Significant
The incidence of H. Pylori positivity is low in groups with low CD4 count 
18% in patients with CD4 <100 and 27 % with CD4 between 100 – 200. 
Those who had higher CD4 counts had higher incidence of RUT 
positivity 39% with CD4 more than 200 and 64% with CD4 more than 
500.
                                    
FIGURE 6 – RUT POSITIVITY IN RELATION TO ART:
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TABLE NO 7 – RUT POSITIVITY AND ART
ART positive negative
No. % No. %
Taken 18 39.1 28 60.9
Not 
taken
21 38.2 34 61.8
p 0.6143    Not 
Significant
The incidence of H.Pylori positivity is not significantly different among 
those  patients who were on ART (18%) and those who were not on 
ART (21%).
                                          
FIGURE 7- BIOPSY FINDINGS
                 
TABLE NO. 8 – BIOPSY FINDINGS
Biopsy Study 
cases
Controls
No. % No
.
%
Normal 38 37.6 31 29.
2
Antral gastritis&/Body 
gastritis
56 55.4 63 59.
4
Lymphoplasmacytic 
infiltration
4 4 10 9.4
adenocarcinoma 1 1 1 1
Intestinalmetaplasia 2 2 1 1
Total 101 100 10
6
100
P 0.2582  Not 
significant
There are overall 63 patients with abnormal biopsy findings in the HIV 
group and 75 patients with abnormal biopsy findings in the control group. 
The incidence of gastritis and lymphoplasmacytic infiltration is higher in 
HIV negative groups, though not statistically significant.
FIGURE 8 – BIOPSY & RUT IN HIV CASES
TABLE NO. 9 – BIOPSY FINDINGS AND RUT AMONG HIV CASES:
Biopsy findings RUT
Positive Negative
No. % No. %
Normal 8 21.1 30 78.9
AG  BG 27 48.2 29 51.8
Lympho plasmacytic infiltration 1 25 3 75
others  Intestinal metaplasia
            Adenocarcinoma
2
1
100
100
-
-
-
-
P value 0.0092     Significant
Among RUT positive patients many (48%) had antral and body gastritis. 
But equal no. of RUT negative patients(51%)  showed gastritis in biopsy. 
TABLE NO 10 – BIOPSY FINDINGS AND CD4 COUNT:
Biopsy findings
CD 4+ T Cell Count 
<100 
cells / µl
100-200 
cells / µl
200-500 
cells / µl
>500 
cells / µl
No
.
% No. % No
.
% No. %
Normal (38) 8 50 10 45.
5
16 39 4 18.
2
AG,BG (56) 5 31.
3
12 55.
5
23 56.
1
16 72.
7
LPI (4) 2 12.
5
- - 1 2.4 1 4.5
Adeno Carcinoma (1) - - - - - - 1 4.5
IntestinalMetaplasia(
2)
1 6.3 - - 1 2.4 - -
Total 16 100 22 100 41 100 22 100
The percentage of abnormal biopsy findings is increasing with increasing 
CD4 Counts. Antral and body gastritis is seen in 31% of pts with CD4 
less than 100, but 72% of pts with CD4 counts more than 500 and 56% 
of pts with CD4 counts 200 – 500 had antral and body gastritis.
              TABLE NO. 11 – BIOPSY FINDINGS AND RUT IN 
CONTROLS
Biopsy findings
RUT
Positive Negative
No % No %
Normal (31) 15 48.4 16 51.6
AG,BG (63) 52 82.5 11 17.5
IM (1) 1 100 - -
AC (1) - - 1 100
LPI(10) 10 100 - -
Total 78 100 28 100
‘p’ 0.0001
Significant
Among the control patients, 82% patients with RUT positivity had 
gastritis, one patient with intestinal metaplasia was RUT positive. One 
patient had adenocarcinoma but the RUT in that patient was negative.
TABLE NO – 12 BIOPSY IN RUT POSITIVE CASES IN BOTH CASES 
& CONTROLS:
Biopsy findings
RUT positive cases in
Study cases Control cases
No % No %
Normal 8 20.5 15 19.2
AG,BG 27 69.2 52 66.7
LMP 1 2.6 10 12.8
Adeno Carcinoma 1 2.6 - -
Intestinal Metaplasia 2 5.1 1 1.3
Total 39 100 78 100
‘p’ 0.9345
Not significant
Among the HIV patients who were RUT positive  approximately 80% 
had abnormal histopathological finding, similarly among the RUT 
positive control 81% of patients had abnormal biopsy findings
TABLE NO 13- Biopsy in RUT negative patients in HIV and control 
group:
Biopsy findings
RUT negative cases in
Study cases Control cases
No % No %
Normal 30 48.4 16 57.1
AG,BG 29 46.8 11 39.3
LPI 3 4.8 - -
Adeno Carcinoma - - 1 3.6
Intestinal Metaplasia - - - -
Total 62 100 28 100
‘p’ 0.5881
Not significant
From this table we can see that though the RUT was negative, 51.6% of 
these patients had abnormal biopsy findings. Similarly 42.9% of control 
patients who were RUT negative had abnormal biopsy findings.
  
TABLE NO 14- ENDOSCOPY FINDINGS IN HIV CASES AND 
CONTROLS:
Endoscopy findings
Study cases Control cases
No % No %
Normal 87 86.1 83 78.3
Oesophageal Moniliasis 10 9.9 - -
Antral growth - - 1 1.0
Multipleulcersesophagus 1 1.0 - -
Gastritis 3 3.0 22 20.7
Total 101 100 106 100
P value 0.1972 insignificant.
The incidence of gastritis in controls was 20% when compared to 3% in 
HIV cases. The incidence of moniliasis in HIV cases was 10%over all, 
but 85% among patients with CD4+ T cell counts <50.  There was 1 
case of antral growth in controls. There was 1 case of multiple 
esophageal ulcers in HIV group.
DISCUSSION
DISCUSSION
Helicobacter pylori has been implied as the most common agent causing 
gastritis in general population.[28][29]. But the incidence of H.pylori infection  in 
HIV positive patients has been controversial.  While there are studies stating 
that  there  is  no  significant  difference  in  HIV  patients  from  the  general 
population,[33] there  are  also  studies  stating  that  the  occurrence  of  Hpylori 
infection is lesser in HIV patients[30][31]. Our study revealed similar observations.
The RUT test is a specific test for H.pylori . In our study , out of 101 HIV 
patients 39 patients, that is, 38.6% were RUT positive, when compared to HIV 
negative control group in which 78 patients were positive, that is, up to 78%, 
which is a very significant difference.
In  a  study  conducted  at  Kenyatta  National  Hospital  Nairobi  by  Ali 
Mohammed F et  al[30],  similar  results were obtained ,  they showed a lower 
incidence of H.pylori within the HIV group (84%) when compared to  the HIV 
negative control group who were 95% positive for RUT.
A much lower incidence of H.pylori in HIV patients was demonstrated 
by,  Lv FJ, Luo Xl et al,[31] who used RUT and biopsy studies. In their study 
H.pylori positivity was as low as 22.1% in HIV patients and the incidence of 
H.pylori in non - HIV patients was 44.8%. 
The  exact  cause  for  this  low prevalence  of  H.pylori  among  the  HIV 
patients is not known but, hypothesised to be impaired acid secretion in AIDS – 
hypochlorhydria, which prevents the initial colonisation of H.pylori in gastric 
mucosa.[32]
But the study done by Battan R, et al[33] showed a different result. Battan 
et al used staining and culture for H.pylori and have shown that 40% of patients 
with  HIV  had  H.pylori  positivity  and  39%  of  HIV  negative  patients  were 
H.pylori positive. Thus they have concluded that there was no difference among 
H.pylori prevalence in HIV and non - HIV patients.
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In our  patients  the  incidence  of  H.pylori  positivity  (RUT)  was  higher 
among patients with higher CD4+ T cell  counts,  when compared to patients 
with low CD4+ T cell  counts,  in HIV group.  In our  study the incidence of 
H.pylori positivity was only 18% in patients with CD4+ T cell counts less than 
100 cells / µl whereas patients with CD4+ T cell counts 200-500 cells / µl and 
>500 cells / µl had 39 and 63.6%  H.pylori  positivity respectively. 
Skwara p et al[34] conducted a study in 94 HIV patients using RUT and 
HPE and divided them into 2 groups based on CD4+ T cell counts, CD4+ T cell 
< 200 cells / µl and CD4+ T cell >200 cells / µl. They have also observed that 
H.pylori  was  low in  severe  immunodeficiency  CD4+  T  cell<200  cells  /  µl 
(40%) and high in patients with CD4+ T cell>200 cells / µl (72%).
Ali  mohammed  et  al[30],  study  also  concluded  that  the  prevalence  of 
Hpylori decreased with decreasing peripheral CD4+ T cell counts.
Also  Lv  Fj  Luo[31] et  al  concluded  that  histopathological  findings 
positive for prevalence of H.pylori displayed a direct correlation with CD4+ T 
cell count stratification in HIV positive patients.
In our study there were 46 HIV patients who were on ART and 55 HIV 
patients, who were not on ART. Our HIV patients, who were on ART showed, 
no significant difference from the patients who were not on ART as for as the 
RUT positivity was concerned. 39.1% of patients on ART were RUT positive 
and 38.2% who were not on ART were also positive. Thus we observed that 
ART has no influence over the H.pylori infection among HIV patients. Mach T 
et al[35] conducted  study in HIV patients using RUT and biopsy for H.pylori and 
other infections in HIV patients. They observed that while the prevalence of 
gastric mucosal changes was not different between the patients treated and not 
treated with ART, H.pylori infection was less frequent in HIV infected patients 
treated with ART.
We have also observed that the incidence of gastritis  was higher in HIV 
pts with higher CD4+ T cell counts. As the CD4+ T cell counts were increasing 
the  percentage  of  gastritis  was  also  increasing  from 31.3% in  patients  with 
CD4+ T cell < 100 cells / µl, 55.5% in patients with CD4+ T cell count 100-200 
cells / µl,  56 % in patients with CD4+ T cell count 200-500 cells / µl, and  to 
72% in patients with CD4+ T cell > 500 cells / µl. This demonstrates a direct 
correlation between CD4+ T cell count and histopathological changes in gastric 
mucosa , in our study.
Similar  observations  of  positive  histopathological  findings  directly 
correlating  with  peripheral  CD4+  T  cell  counts  was  noted  in  the  study 
conducted by Fabris P et al[36]. They have noticed that HIV patients with CD4+ 
T cell counts less than 100 cells / µl have 43% positive biopsy findings whereas 
patients with CD4+ T cell  count more than 200 cells /  µl had 78% positive 
biopsy findings.
Among  the  control  group  H.pylori  positivity  was  seen  in  82.1%  of 
patients  with  gastritis  and  patients  who  had  Intestinal  metaplasia, 
Adenocarcinoma  and  100%  of  patients  who  had  lymphoplasmocytic 
infiltrations, were Hpylori positive. Hence H.pylori has proven to be the most 
common  cause  of  gastritis  in  general  population,  as  shown  in  world 
literature[28,29,37,38].
One  conflicting  observation  noted  in  this  study  was  the  presence  of 
significant  gastritis  (50%),  in  HIV patients  who  were  RUT negative.  Other 
causes of gastritis in HIV patients are  opportunistic infections such as gastric 
CMV infection, herpes,  toxoplasmosis and cryptosporidiosis. But neither did 
we  find  any  endoscopic  lesions  nor  biopsy  findings  suggestive  of  these 
organisms  in  our  cases.  Due  to  the  patchy  distribution  of  these  organisms 
multiple  biopsy  samples  are  required  and  also  these  organisms  require 
immunohistological  staining and cultures.   Reaching a specific diagnosis  of 
gastritis in HIV patients has been difficult in many studies. In 2 studies Rolston 
et al[39] and  Lim SG et al[40] in which patients with  HIV and gastroduodenal 
disease underwent endoscopy with biopsies  specific diagnoses could be made 
in only 42%  and 46% of patients respectively. ART is yet another possibility 
for dyspepsia and gastritis in HIV patients, as noticed in study conducted by 
Wernet Silva AL et al[41]. In our study 13 patients on ART showed gastritis in 
the  abscence  of  H.pylori  positivity.  Also  we  have  not  found  any  cases  of 
Kaposi’s Sarcoma  or Lymphoma in our biopsy samples of HIV patients. May 
be a larger sample size could have demonstrated these.
The endoscopic observation in our study cases was normal  in 87% of 
HIV  patients  and  83%  of  non  HIV  patients.  While  gastritis  was  seen 
macroscopically  in  22%  of  control  patients  only  3%  of  HIV  patients 
demonstrated endoscopic appearance of gastritis. One control patient had antral 
growth.  While  one  HIV patient  demonstrated  adenocarcinoma  in  biopsy  no 
gross lesion was found in endoscopy of this patient. Multiple esophageal ulcers 
were  seen  in  esophagus  in  one  HIV patient,  but  the  biopsy  in  this  patient 
revealed nonspecific inflammatory cell infiltration.
We have also noticed that the incidence of esophageal moniliasis in HIV 
patients was only 10% which is low when compared to observed prevalence 
among AIDS patients.  This is due to the CD4+ T cell count variation in our 
study. In our study there were only 7 patients who had CD4+ T cell counts less 
than 50 cells / µl. And 6 of these patients had esophageal moniliasis, that is upto 
86% among patients with CD4+ T cell  counts less than 50 cells / µl. Narvarte 
G[42], et al study also showed that the incidence of moniliasis in HIV patients 
with CD4+ T cell counts less than 50 cells / µl was around 84 to 88% . Olmos 
MA, et al[43], is another study that evaluated the endoscopic findings in 132 HIV 
patients. And they have observed a lower  incidence of esophageal moniliasis of 
28.4% , but all of them had a low mean CD4+ T cell count.  Three other patients 
who  had  CD4  counts  50-100  cells  /  µl  showed  esophageal  candidiasis  in 
endoscopy,  but  these  patients  were  not  receiving  fluconazole.  All  the  other 
patients  who  did  not  have  any  endoscopic  appearance  for  candidiasis  were 
receiving fluconazole either as therapeutic or as a prophylactic measure. So we 
attribute the decreased presence of moniliasis in our HIV group to fluconazole 
administration and varying CD4+T cell counts in the study sample. 
SUMMARY
SUMMARY
The  study  “EVALUATION  OF  FINDINGS  OF  UPPER 
GASTROINTESTINAL ENDOSCOPY IN HIV POSITIVE PATIENTS WITH 
SPECIAL  REFERENCE  TO  HELICOBACTER  PYLORI”,  was  a  cross 
sectional  study  of  101 HIV patients  and 106  HIV negative  control  patients 
admitted  with  complaints  of  dyspepsia,  at  Government  Rajaji  Hospital, 
Madurai.
After detailed history, physical examination and basic investigations, all 
patients underwent endoscopy and gastric mucosal samples were analysed for 
rapid urease tests and histology.
There was decreased prevalence of Helicobacter pylori in HIV positive 
patients and the prevalence was directly related to CD4+ T cell counts in HIV 
patients. No significant influence with ART was seen. Esophageal moniliasis 
was found to be the most common upper GI disease in HIV patients.  
Possible cause for this decreased prevalence of H.pylori in HIV patients 
could be the hypochlorhydria in HIV patients which prevents colonisation of 
H.pylori.
CONCLUSION
CONCLUSION
1) In the endoscopic findings the most common opportunistic infection in 
HIV positive patients was esophageal candidiasis.
2) There is decreased positivity of H.pylori in HIV patients when compared 
to controls. This is consistent with literature reported world wide.
3) Amongst the HIV patients, those whose CD4+ T cell counts were < 100 
cells / µl had lower H.pylori status than those whose CD4+ T cell counts 
were >500 cells / µl.
4) Prevalence of H.pylori did not seem to be altered with ART.
5) The histology of the gastric mucosa was no different in H.pylori positive 
or negative subjects with HIV.
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APPENDIX
PROFORMA
SNO:
NAME:                                                  OCCUPATION:
AGE/SEX:                                               ADDRESS:
WARD-UNIT:                                      OGD NO:
I.P/O.P NO:                                              BIOPSY NO:
H/O PRESENT ILLNESS:
UPPER GIT SYMPTOMS:                  DURATION
DYSPHAGIA:                          Y/N
ODYNOPHAGIA:                      Y/N
MUCOCUTANEOUS ULCERS:   Y/N
EPIGASTRIC PAIN:                    Y/N
BLOATING SENSATION:              Y/N
HEART BURN:                         Y/N
VOMITTING:                           Y/N
ABDOMINAL MASS:                   Y/N
C/O:
CHRONIC DIARRHOEA:              Y/N
FEVER:                                 Y/N
LOSS OF WEIGHT:                     Y/N
CHRONIC COUGH:                    Y/N
OTHER COMPLAINTS:
PAST HISTORY:
Systemic illness:
Drug history:      ART /ATT/Anti-H.pylori regime/
                   PPI/Metronidazole/NSAIDS/Others.
H/O blood transfusions:
PERSONAL HISTORY:
MARITAL STATUS:- married/unmarried/widow/widower/abandoned
H/O Exposure: - premarital/ extramarital
Sexual habits: - hetero/homo/bisexual
H/O alcoholism/smoking:
FAMILY HISTORY:
GENERAL EXAMINATION:
PALLOR -                    ICTERUS -                     WASTING -
GENERALISED LYMPHADENOPATHY -                             
VITALS:      P.R - 
               B.P -
GASTROINTESTINAL EXAMINATION: 
ORAL CANDIDIASIS
OHL 
EPIGASTRIC TENDERNESS
ABDOMINAL MASS
OTHER FINDINGS
OTHER SYSTEMS:
CLINICAL DIAGNOSIS:
INVESTIGATIONS:
Blood glucose:
S.urea:
S.creatinine:
Hb%:
TC:
DC:  L-        N-       E-        M-        B-
ELISA   for     HIV - 1
                  HIV - 2
UGI  ENDOSCOPY: 
RAPID UREASE TEST:
HISTOPATHOLOGY:
FINAL DIAGNOSIS:
MASTER CHART
S. 
No
AGE /
SEX
SYMPTO
MS DRUGS G/E ABD
CD4
C
CD4 
Grou
p
OGD RUT
BIOPS
Y
1 33/M PRE A,R, N ET 570 CD4 N — AGBG
2 50/F PRE A,R, CLN N 350 CD3 N † AGBG
3 35/M PRE NA N N 715 CD4 N † AGBG
4 36/M ABS NA,CO,FL W N 192 CD2 N — AGBG
5 39/F PRE NA,CO,FL CLN,W N 318 CD3 N — AGBG
6 54/M ABS NA,CO,FL W,OC,CLN N 33 CD1 OM — AGBG
7 39/M PRE NA W,OC, N 229 CD3 OM — AGBG
8 25/M PRE A W N 812 CD4 N † AGBGLF
9 32/M PRE A,CO,FL W,OC,CLN N 126 CD2 N — AGBG
10 27/M PRE A CLN N 205 CD3 N † AGBG
11 52/M PRE NA N N 486 CD3 N — AGBG
12 35/F PRE NA W,CLN,OC N 231 CD3 OM — AGBG
13 65/F PRE NA W,CLN,OC N 34 CD1 OM — AGBG
14 30/F ABS NA W,CLN N 419 CD3 N — N
15 27/M ABS NA W,OC N 195 CD2 N — AGBG
16 45/M ABS NA,TB W,CLN,OC N 267 CD3 N — N
17 25/M ABS NA,CO,FL W,CLN N 202 CD3 N † AGBG
18 24/M ABS NA W,OC N 195 CD2 N — AGBG
19 47/M PRE A,TB,R,COFL
W,CLN,O
C N 14 CD1 OM — N
20 35/M PRE NA W,CLN,OC N 372 CD3 N † AGBG
21 45/M ABS NA,TB W,CLN,OC N 267 CD3 N — AGBG
22 32/F PRE A N N 560 CD4 N — AGBG
23 35/F PRE NA N N 660 CD4 N † AGBG
24 29/F ABS NA,TB N N 432 CD3 N — N
25 23/F PRE A W ET 215 CD3 N — AGBG
26 55/M PRE A,CO,FL OC N 62 CD1 MU — NSI
27 38/M PRE NA CLN N 373 CD3 N — AGBG
28 23/F ABS NA OC,W N 213 CD3 N † AGBG
29 46/M ABS NA W,OC,CLN N 38 CD1 OM — N
S. 
No
AGE /
SEX
SYMPTO
MS DRUGS G/E ABD
CD4
C
CD4 
Grou
p
OGD RUT
BIOPS
Y
30 49/F PRE NA OC,W N 370 CD3 N — AGBG
31 19/F ABS NA CLN,W N 475 CD3 N † AGLF
32 25/M PRE NA OC N 815 CD4 N — AGBG
33 28/M PRE NA CLN,W N 184 CD2 DAG † AGBG
34 55/M PRE A,TB W ASC 252 CD3 N — N
35 42/M ABS NA N N 469 CD3 N — N
36 35/F PRE NA N N 996 CD4 N † AGBG
37 32/F ABS NA N N 1010 CD4 N — AGBG
38 40/M PRE A,CO,FL W,OC N 57 CD1 N — N
39 45/M PRE NA N N 388 CD3 N — AGBG
40 22/F PRE A,R, W ET 365 CD3 N — AGBG
41 31/F ABS A W,OC N 202 CD3 N — N
42 30/F PRE A,CO,FL OC N 158 CD2 N — N
43 21/M PRE NA N N 612 CD4 N † AGBG
44 30/F PRE NA W,OC N 48 CD1 OM — AGBG
45 31/M ABS A,CO,FL OC,W,CLN H† 123 CD2 N — AGBG
46 28/F PRE NA N N 665 CD4 N — AGBG
47 50/M PRE A,CO,FL W N 141 CD2 N — AGBG
48 31/M PRE
,
A,TB,CO,F
L
W S† 77 CD1 N — LPI
49 40/M PRE A W N 370 CD3 N — LPI
50 30/F PRE NA N N 774 CD4 N † LPI
51 32/M PRE NA OC,CLN,W N 75 CD1 OM — LPI
52 59/M PRE A,CO,FL N N 45 CD1 N — AGBG
53 28/M PRE A,CO,FL W ET 113 CD2 N — N
54 40/F PRE A,CO,FL N ET 107 CD2 N — N
55 28/M PRE NA CLN,W N 325 CD3 N — N
56 55/M PRE NA W,CLN,OC N 189 CD2 N — AGBG
57 34/F PRE NA W,OC N 249 CD3 N — N
58 32/M ABS NA W,OC N 188 CD2 N † N
59 36/M ABS A,CO,FL W N 64 CD1 N † IM
60 36/M PRE NA W ET 200 CD2 N — N
61 49/M PRE NA N N 195 CD2 N — N
62 62/M ABS NA W,OC N 53 CD1 OM — N
S. 
No
AGE /
SEX
SYMPTO
MS DRUGS G/E ABD
CD4
C
CD4 
Grou
p
OGD RUT
BIOPS
Y
63 38/M PRE A,CO,FL OC N 129 CD2 N † AGBG
64 37/M PRE A,TB,CO,FL OC N 70 CD1 N — N
65 29/F ABS TB W,OC N 153 CD2 N — N
66 28/F PRE NA N N 891 CD4 N † N
67 38/M PRE NA W N 755 CD4 N † AC
68 34/F PRE NA N N 1071 CD4 N † AGBG
69 30/F ABS NA CLN N 1080 CD4 N † AGBG
70 52/M PRE NA N N 417 CD3 N † AGBG
71 30/M ABS NA,TB N N 256 CD3 N — N
72 42/M PRE NA OC,W N 295 CD3 N — N
73 25/F PRE A,CO W N 322 CD3 N † N
74 37/M PRE ,A,CO,FL OC,W ET,H†,S† 102 CD2 N — AGBG
75 54/M PRE A,CO,FL OC,W N 142 CD2 N † AGBG
76 35/M PRE A N N 1101 CD4 N — AGBG
77 37/F ABS NA W N 668 CD4 N † AGBG
78 34/M ABS A N N 542 CD4 N † AGBGLF
79 42/M PRE A N N 475 CD3 N † N
80 37/M PRE NA W,OC ASC,H† 269 CD3 N — N
81 47/M ABS A,CO,FL W N 170 CD2 N — N
82 31/M PRE A,CO,FL W,OC ASC,ET 107 CD2 N †
AGBGL
F
83 55/F PRE A,CO,FL W,OC ET 101 CD2 DB — N
84 30/F PRE NA N N 878 CD4 N † N
85 45/M PRE NA N N 496 CD3 N — N
86 35/M PRE A W N 327 CD3 N † IM
87 26/M PRE A N N 268 CD3 N — N
88 38/M PRE A,CO,FL W,OC N 61 CD1 OM † N
89 34/M PRE A N N 398 CD3 N † AGBG
90 34/M ABS A,TB OC,W N 585 CD4 N — N
91 26/F PRE A,TB N ET 1197 CD4 N — N
92 25/F PRE A,R,CO N N 652 CD4 N † AGBG
93 55/M ABS A,CO,FL W,OC N 50 CD1 N — AGBG
94 30/M PRE A,CO,FL W,OC N 89 CD1 N † N
S. 
No
AGE /
SEX
SYMPTO
MS DRUGS G/E ABD
CD4
C
CD4 
Grou
p
OGD RUT
BIOPS
Y
95 49/M PRE A N ET 251 CD3 N † AGBGLF
96 30/M PRE A,CO,FL OC,W N 171 CD2 N † N
97 37/M PRE A,TB W N 204 CD3 N — N
98 35/M ABS NA N N 350 CD3 N † AGBG
99 25/M PRE NA N N 270 CD3 DAG,DU †
AGBGL
F
10
0 30/F PRE NA W, N 232 CD3 N † AGBG
10
1 30/M ABS A W,OC N 313 CD3 N † AGBG
S.N
o AGE/SEX SYMPTOMS
DRUG
S G/E ABD OGD RUT BIOPSY
1 32/M PRE _ N N N † N
2 28/F PRE _ N N N — AGBG
3 48/M PRE _ N N N — N
4 24/M PRE _ N N N — N
5 23/M PRE _ N N N † AG
6 35/F PRE _ N N N † N
7 45/M PRE _ N N N † AG
8 42/F PRE _ N ET N † BG
9 18/F PRE _ N N N † AG
10 35/F PRE _ N N N † AG
11 43/M PRE _ N ET N † BG
12 40/M PRE _ N ET N † BG
13 32/M PRE _ N ET G † N
14 20/M PRE _ N N N † AGBG
15 39/F PRE _ N N N — N
16 45/M PRE _ N N N † AG
17 75/M PRE _ N ET G † AGBG
18 19/M PRE _ N N N — N
19 70/F PRE _ N N N † AG
20 25/F PRE _ N N G † PG
21 26/F PRE _ N ET G † AG
22 55/M PRE _ N ET G † AG
23 43/M PRE _ N ET G † AGBG
S.N
o AGE/SEX SYMPTOMS
DRUG
S G/E ABD OGD RUT BIOPSY
24 21/M PRE _ N ET N † N
25 30/M PRE _ N ET N † AG
26 75/M PRE _ N ET N † AGBG
27 58/M PRE _ N ET N † AG
28 28/F PRE _ N ET G † AGBG
29 52/M PRE _ N N N † AG
30 35/F PRE _ N N N — N
31 45/M PRE _ N N N † AG
32 30/M PRE _ N ET G † AG
33 30/F PRE _ N ET N † N
34 60/M PRE _ N ET N † N
35 30/F PRE _ N ET G † AG
36 37/M PRE _ N N G — AGBG
37 28/M PRE _ N ET G † AG
38 60/F PRE _ N ET N † AGBG
39 36/F PRE _ N ET G † AGBG
40 52/M PRE _ N ET N † AGBG
41 28/M PRE _ N ET G † AG
42 65/M PRE _ N ET N — FG
43 58/F PRE _ N ET N — FG
44 45/F PRE _ N ET N † FG
45 45/M PRE _ N ET G † AG
46 24/M PRE _ N ET N † N
47 66/M PRE _ N ET N † PG
48 35/M PRE _ N ET N † IM
49 42/M PRE _ N ET N — BG
50 37/M PRE _ N ET N — N
51 42/M PRE _ N ET N † AG
52 29/M PRE _ N ET N † AGBG
53 50/F PRE _ N ET N † AGBG
54 66/M PRE _ N ET N — AG
55 33/M PRE _ N ET N † N
56 37/M PRE _ N ET N † AG
57 49/F PRE _ N ET N — AGBG
58 37/M PRE _ N N N † AG
59 37/M PRE _ N ET G † AG
60 59/F PRE _ N N N — N
S.N
o AGE/SEX SYMPTOMS
DRUG
S G/E ABD OGD RUT BIOPSY
61 56/M PRE _ N ET N † AGBG
62 54/M PRE _ N ET N † AG
63 60/F PRE _ N N N † AGBG
64 36/F PRE _ N N N † AGBG
65 38/F PRE _ N N N † AGBG
66 52/F PRE _ N N N † N
67 60/F PRE _ N ET N — N
68 40/F PRE _ N ET N † AGBG
69 28/F PRE _ N ET N † BGAG
70 50/F PRE _ N ET AGR — AC
71 26/F PRE _ N ET N † AG
72 56/M PRE _ N ET N — N
73 30/F PRE _ N N N — AGBG
74 55/F PRE _ N N G † AG
75 19/F PRE _ N N N — N
76 60/F PRE _ N N N — N
77 38/M PRE _ N N N † N
78 60/M PRE _ N ET G † LPI
79 62/M PRE _ N ET N † FG
80 31/M PRE _ N N N † N
81 60/F PRE _ N N N † LPI
82 46/M PRE _ N ET G † LPI
83 27/M PRE _ N ET G † LPI
84 32/M PRE _ N N N † N
85 33/M PRE _ N ET N † PG
86 65/M PRE _ N N N — N
87 73/F PRE _ N ET N † LPI
88 60/M PRE _ N ET N † N
89 37/M PRE _ N ET N † N
90 24/M PRE _ N ET G † LPI
91 45/F PRE _ N N N † LPI
92 35/F PRE _ N N N † AGBG
93 50/F PRE _ N N N † PG
94 42/M PRE _ N N N — N
95 45/M PRE _ N N N — LPI
96 37/F PRE _ N N N † LPI
97 52/F PRE _ N N N — N
S.N
o AGE/SEX SYMPTOMS
DRUG
S G/E ABD OGD RUT BIOPSY
98 47/M PRE _ N N N — N
99 32/M PRE _ N N N † BGAG
100 70/M PRE _ N N N — AG
101 45/F PRE _ N N N † N
102 64/M PRE _ N N N — AGBG
103 62/F PRE _ N N N † AG
104 44/M PRE _ N N G † AG
105 38/M PRE _ N N N — N
106 45/M PRE _ N N N † LPI
KEY TO MASTER CHART
M – MALE
F – FEMALE
G/E -  GENERAL EXAMINATION
ABD -  ABDOMEN EXAMINATION
N –NORMAL
CLN – CERVICAL LYMPHADENOPATHY
W – WASTING
OC – ORAL CANDIDIASIS
A – Pt on ART
NA – Pt not on ART
R – RANTAC
CO – COTRIMOXAZOLE
FL – FLUCONAZOLE
TB – ANTI TB DRUGS
ET – EPIGASTRIC TENDERNESS
ASC – ASCITES
H† - HEPATOMEGALY
S† - SPLEENOMEGALY
CD4C – CD4 COUNT 
CD1 – CD4 COUNT <100
CD2 – CD4 COUNT 100-200
CD3 – CD4 COUNT 200-500
CD4 – CD4 COUNT >500
OGD – ENDOSCOPY
OM – OESOPHAGEAL MONILIASIS
MU – MULTIPLE ULCERS
AGBG – ANTRAL GASTRITIS, BODY GASTRITIS
LPI – LYMPHOPLASMACYTIC INFILTRATION
IM - INTESTINAL METAPLASIA
AC – ADENOCARCINOMA
ABBREVIATIONS
AIDS - acquired immunodeficiency syndrome
ART - anti retro viral therapy
EIA - enzyme immune assay
ELISA – enzyme linked immunosorbent assay
HIV -  human immunodeficiency virus
HPE - histopathological examination
NSAID – non steroidal anti inflammatory drugs
PPI - proton pump inhibitors
RUT - rapid urease test
